AI Article Synopsis
- Used CDC data and a Markov model to identify the best age for single-dose pneumococcal conjugate vaccine (PCV) administration.
- Considered protective antibody thresholds of 0.35 and 1.0 mcg/ml and focused on invasive pneumococcal disease (IPD) occurrence at 24 months.
- Results suggested vaccinating at 5-7 months with immune memory and 8-10 months without memory, potentially reducing IPD cases by 15 to 62%.
Article Abstract
Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2005.08.092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!